The Oncology Podcast

The Oncology Network
  • 4.8 (20)
  • Medicine
  • Updated Fortnightly

The Oncology Podcast including The Oncology Journal Club Podcast by Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson; and Supportive Care Matters by Dr. Bogda Koczwara.Oncology News and Expert Analysis from a unique Australian viewpoint. Proudly brought to you by The Oncology Network. The Oncology Network are producers of digital resources that support busy oncology health professionals. For more information visit our website www.oncologynetwork.com.au.We also invite Healthcare Professionals to subscribe to The Oncology Newsletter and our Oncology Portal for free and exclusive resources at: www.oncologynetwork.com.au

  1. The OJC ASCO 2026 Special Part 2

    13 June

    The OJC ASCO 2026 Special Part 2

    Send us Fan Mail S4E5 The Oncology Journal Club Podcast  The Oncology Journal Club team returns with Part 2 of its ASCO 2026 coverage, delivering a whirlwind tour through some of the most interesting studies presented across gastrointestinal, breast, lung, genitourinary, gynaecological, skin and haematological cancers. Craig Underhill, Kate Clarke and Christopher Jackson discuss emerging data on ctDNA-guided treatment strategies, exercise as adjuvant therapy, genomic testing in breast cancer, novel antibody-drug conjugates, immunotherapy advances, de-escalation studies and potential new standards of care. They also explore the growing role of precision medicine, evolving treatment sequencing strategies and the challenges facing the global oncology workforce. Along the way, expect the usual OJC banter, ASCO bingo, questionable drug pronunciations and a recurring tribute to Qantas pyjamas! The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

    50 min
  2. The OJC ASCO 2026 Special Part 1

    9 June

    The OJC ASCO 2026 Special Part 1

    Send us Fan Mail S4E4 The Oncology Journal Club Podcast In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting’s most talked-about studies and discuss what they could mean for clinical practice. From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care. The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community. Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment. The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

    48 min
  3. S4E3 The Oncology Journal Club Podcast: ‘Mouthwatering’ RAS(ON), Bob Marley’s Melanoma, ADT Hot Flushes + Prostate Cancer Terminology

    20 May

    S4E3 The Oncology Journal Club Podcast: ‘Mouthwatering’ RAS(ON), Bob Marley’s Melanoma, ADT Hot Flushes + Prostate Cancer Terminology

    Send us Fan Mail In this episode of The Oncology Journal Club, the team cover one of the most talked-about pancreatic cancer papers of the year, unpacking the promising early results for daraxonrasib in previously treated RAS-mutated pancreatic cancer and the science behind new RAS(ON) therapeutics.  The team also discuss a fascinating phase II study of single-cycle neoadjuvant pembrolizumab in MMR-deficient colon cancer, new recommendations from the Prostate Cancer Working Group 4 and why the terminology we use in prostate cancer matters. Along the way, there’s discussion of Bob Marley’s acral melanoma, multidisciplinary lung cancer meetings, androgen receptor-positive TNBC, HER2-mutant lung cancer and whether oxybutynin could help men experiencing androgen deprivation-related hot flushes. The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.

    45 min
  4. The PBS Update May 2026: Fruquinitinib for eligible mCRC patients + new haematology options

    8 May

    The PBS Update May 2026: Fruquinitinib for eligible mCRC patients + new haematology options

    Send us Fan Mail Proudly Produced by The Oncology Network Professor Craig Underhill and Rachael Babin break down the key oncology changes from the May 2026 PBS update. This month we run through 3 fresh PBS listings that affect Australian oncology and haematology practice, from fruquintinib, a late-line colorectal cancer treatment, through to new haematology options.   Follow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals. Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

    17 min
  5. S4 E2 The Oncology Journal Club: Chrono-Oncology, Genomic Therapy Matching + iCCA

    23 Apr

    S4 E2 The Oncology Journal Club: Chrono-Oncology, Genomic Therapy Matching + iCCA

    Send us Fan Mail In this episode of The Oncology Journal Club, the team weigh promising trial signals against the level of evidence needed to change clinical practice. From perioperative cholangiocarcinoma to molecular matching and chrono-oncology, the focus stays on a key question: what meaningfully improves outcomes for patients? What’s covered  NeoGOLP trial in high-risk resectable iCCA: improved event-free survival; overall survival still immature  MoST programme: molecular matching and survival associations when therapies align with biomarkers  Genomic therapy matching in clinical decision-making  Chrono-oncology: does treatment timing influence outcomes?  CHOPIN phase II uveal melanoma trial: combination therapy signals and feasibility  ASCO living guideline updates across lung, gastro-oesophageal and thyroid cancers The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.

    38 min
  6. The PBS Update April 2026: Expanded Indications + New Rare Cancer Options

    15 Apr

    The PBS Update April 2026: Expanded Indications + New Rare Cancer Options

    Send us Fan Mail Proudly Produced by The Oncology Network Professor Craig Underhill and Rachael Babin break down the key oncology changes from the April 2026 PBS update. This month we run through six fresh PBS listings and policy changes that affect Australian oncology and haematology practice, from ROS1-positive non small cell lung cancer to perioperative immunotherapy and late-line blood cancer options.  We focus on who benefits, what the key trial signals are and what clinicians need to monitor so access translates into safe, real-world outcomes.  Repotrectinib listed for ROS1-positive NSCLC, including activity after prior TKIs and in resistant mutations, plus monitoring for dizziness and pneumonitis Durvalumab listed for muscle-invasive bladder cancer using the Niagara perioperative regimen, balancing survival gains with immune-related toxicity Three new pembrolizumab listings across cervical cancer, adjuvant renal cell carcinoma and perioperative head and neck cancer, with discussion of endpoints and eligibility Haematology additions including a BCMA bispecific for relapsed myeloma, an oral kinase inhibitor for higher-risk myelofibrosis and mogamulizumab for cutaneous T-cell lymphoma PBS price cuts via generics and biosimilars, plus expanded supervised prescribing for some medicines by nurse practitionersFollow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals. Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

    20 min
  7. The PBS Update March 2026: Landmark Ipi–Nivo Listing + Toripalimab and Cabozantinib

    9 Mar

    The PBS Update March 2026: Landmark Ipi–Nivo Listing + Toripalimab and Cabozantinib

    Send us Fan Mail Australia’s PBS has introduced it’s first pan-tumour reimbursement listing for the immunotherapy combination nivolumab plus ipilimumab. In this inaugural episode of PBS Update, Professor Craig Underhill and Rachael Babin break down the key oncology changes from the March 2026 PBS update, including new listings for toripalimab and cabozantinib. Follow PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals. Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.

    16 min
  8. S4 E1 The Oncology Journal Club: Hot Flushes, Aspirin and AI

    5 Mar

    S4 E1 The Oncology Journal Club: Hot Flushes, Aspirin and AI

    Send us Fan Mail The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson | Proudly Produced by The Oncology Network Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.  We explore practical wins and bold ideas across supportive care, colorectal cancer prevention, immunotherapy timing, digital triage and equity. From halving hot flushes with an NK1/NK3 blocker to biomarker-guided aspirin in colon cancer, we weigh value, risk and what truly improves lives. • Elinzanetant cutting severe hot flushes and improving treatment adherence • Current non-hormonal options and gaps in symptom control • Biomarker-selected aspirin reducing recurrences in colorectal cancer • Limits of DFS, toxicity trade-offs and subgroup signals • Rising early-onset colorectal cancer and system planning needs • Possible environmental and microbiome drivers under study • ASCO geriatric assessment guidance and G8 screening in clinics • PD-1 with short-course radiotherapy boosting rectal pCR rates • Large language models for safe, efficient symptom triage • Rare cancers report on access, cost, and rural inequities • Telehealth standards to link expertise closer to home • Healthy workplace culture to retain a resilient oncology workforce Join the Oncology Network, registration is free, and leave us a voice note on the OJC page at oncologynetwork.com.au. Physicians, don’t forget you can claim CME points for listening to the show! Thanks for listening

    44 min
See All (166)

4.8
out of 5
20 Ratings

About

The Oncology Podcast including The Oncology Journal Club Podcast by Professor Craig Underhill, Dr Kate Clarke and Professor Christopher Jackson; and Supportive Care Matters by Dr. Bogda Koczwara.Oncology News and Expert Analysis from a unique Australian viewpoint. Proudly brought to you by The Oncology Network. The Oncology Network are producers of digital resources that support busy oncology health professionals. For more information visit our website www.oncologynetwork.com.au.We also invite Healthcare Professionals to subscribe to The Oncology Newsletter and our Oncology Portal for free and exclusive resources at: www.oncologynetwork.com.au

Information

  • Creator
    The Oncology Network
  • Years Active
    2020 - 2026
  • Episodes
    166
  • Rating
    Explicit
  • Copyright
    © 2026 Oncology Network Pty Ltd
  • Show Website
    The Oncology Podcast

You Might Also Like